Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With expert's help, Talon wins ODAC support for Marqibo

This article was originally published in Scrip

Executive Summary

Talon Therapeutics came out a winner at the 21 March meeting of the US FDA's Oncologic Drugs Advisory Committee (ODAC) after putting the reins of the firm's experimental drug Marqibo (vincristine sulfate liposomes injection) into the skillful hands of leukaemia expert Dr Susan O'Brien, who masterfully rode that dark horse all the way to the finish line.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts